Consolidation Treatment for Primary Central Nervous System Lymphoma in Younger Patients
After induction chemotherapy for primary central nervous system lymphoma (PCNSL), consolidation is a critical phase. The optimal approach depends on patient age, organ function, and depth of response — making structured, evidence-based guidance essential.
Clinical scenario: Patients with PCNSL who are younger (up to approximately 65–70 years of age) and have suitable organ function, at the consolidation phase of treatment.
Consolidation approach — partial overview
For younger eligible patients, the consolidation strategy centres on intensive chemotherapy-based treatment. An alternative approach exists for patients based on their response status. The complete evidence-based protocol — including the preferred regimen, the criteria for selecting between strategies, and guidance for those with residual disease — is available in full via the link below.
References
DOI: 10.1093/neuonc/noac196
- HDC/ASCT as consolidation is an effective treatment for younger (age up to 65–70) patients with newly-diagnosed PCNSL, though risk of acute toxicity should be taken into account (Level B).
- High-dose thiotepa-based conditioning chemotherapy should be preferred over the BEAM regimen (Level B).
- Reduced dose WBRT consolidation (23.4–30 Gy in 1.8–2.0 Gy fractions) in CR patients is a therapeutic option that is currently being investigated in randomized trials.
- In patients with progressive or significant residual disease after primary chemotherapy, a total dose of 36–40 Gy with a 1.8–2 Gy dose/fraction appears advisable.
View source ↗